PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization

Clinical Trial Platform Uncovers Hidden Signals and Optimizes Next Steps for More Adaptive, Successful, and Efficient Clinical Trials

BOSTON, Oct. 24, 2023 /PRNewswire/ -- PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 million in funding, led by Viola Ventures and Exor Ventures, including participation from LionBird and a group of prominent angel investors.

Read more at prnewswire.com